Endocrine therapies related to anti-estrogen signals for ER-positive breast cancer can be classified into those that target estrogen receptors and those that target estrogen synthesis based on their different mechanisms of action (Burstein2019, Rej et al. 2024). This evidence concerns the gene ESR1 and breast cancer.